• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ABT-450/r-ombitasvir 和 dasabuvir 联合利巴韦林治疗 HCV。

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

机构信息

From Johann Wolfgang Goethe University, Frankfurt am Main (S.Z.), and Medizinische Hochschule Hannover, Hannover (H.W.) - both in Germany; Weill Cornell Medical College, New York (I.M.J.), and Premier Medical Group of the Hudson Valley, Poughkeepsie (P.V.) - both in New York; AbbVie, North Chicago (T.B., J.X., T.P.-M., B.D.-T., L.L., T.P., B.B.), and Center for Liver Diseases, University of Chicago Medical Center, Chicago (D.M.J.) - both in Illinois; Centro Hospitalar de Lisboa Norte and Medical School of Lisbon, Lisbon, Portugal (R.T.M.); Texas Liver Institute, University of Texas Health Science Center, San Antonio (F.P.); Hôpital Saint Joseph, Marseille, France (M.B.); Johns Hopkins University, Baltimore (M.S.S.); Liver and Intestinal Research Centre, Vancouver, BC, Canada (E.T.); St. Vincent's Hospital (Melbourne), Fitzroy, Australia (P.D.); Saint Louis University, St. Louis (A.M.D.); and Southern California Liver Centers and Southern California Research Center, Coronado (T.H.).

出版信息

N Engl J Med. 2014 Apr 24;370(17):1604-14. doi: 10.1056/NEJMoa1401561. Epub 2014 Apr 10.

DOI:10.1056/NEJMoa1401561
PMID:24720679
Abstract

BACKGROUND

In this phase 3 trial we evaluated the efficacy and safety of the interferon-free combination of ABT-450 with ritonavir (ABT-450/r), ombitasvir (also known as ABT-267), dasabuvir (also known as ABT-333), and ribavirin for the retreatment of HCV in patients who were previously treated with peginterferon-ribavirin.

METHODS

We enrolled patients with HCV genotype 1 infection and no cirrhosis who had previously been treated with peginterferon-ribavirin and had a relapse, a partial response, or a null response. Patients were randomly assigned in a 3:1 ratio to receive coformulated ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, and 25 mg of ombitasvir) and dasabuvir (250 mg twice daily) with ribavirin (1000 or 1200 mg daily) or matching placebos during the 12-week double-blind period. The primary end point was the rate of sustained virologic response 12 weeks after the end of study treatment. The primary efficacy analysis compared this rate among patients assigned to the active regimen with a historical response rate (65%) among previously treated patients with HCV genotype 1 infection and no cirrhosis who had received retreatment with telaprevir and peginterferon-ribavirin.

RESULTS

A total of 394 patients received at least one study-drug dose. In the active-regimen group, 286 of 297 patients had a sustained virologic response at post-treatment week 12, for an overall rate of 96.3% (95% confidence interval, 94.2 to 98.4). This rate was noninferior and superior to the historical control rate. Rates were 95.3% among patients with a prior relapse (82 of 86 patients), 100% among patients with a prior partial response (65 of 65 patients), and 95.2% among patients with a prior null response (139 of 146 patients). Pruritus occurred more frequently with the active regimen (in 13.8% of patients) than with placebo (5.2%, P=0.03). Three patients in the active-regimen group (1.0%) discontinued the study drugs owing to adverse events. Hemoglobin values of grade 2 (8.0 to <10.0 g per deciliter) and grade 3 (6.5 to <8.0 g per deciliter) occurred in 4.7% and 0.3% of patients in the active-regimen group, respectively.

CONCLUSIONS

Rates of response to a 12-week interferon-free combination regimen were more than 95% among previously treated patients with HCV genotype 1 infection, including patients with a prior null response. (Funded by AbbVie; SAPPHIRE-II ClinicalTrials.gov number, NCT01715415.).

摘要

背景

在这项 3 期试验中,我们评估了 ABV-450 联合利托那韦(ABT-450/r)、奥比他韦(又名 ABT-267)、达沙布韦(又名 ABT-333)和利巴韦林在既往接受过聚乙二醇干扰素-利巴韦林治疗的 HCV 患者中的疗效和安全性。

方法

我们招募了患有 HCV 基因型 1 感染且无肝硬化的患者,这些患者既往接受过聚乙二醇干扰素-利巴韦林治疗,并且发生了复发、部分应答或无应答。患者以 3:1 的比例随机分配,接受 coformulated ABT-450/r-ombitasvir(ABT-450 的每日剂量为 150mg、ritonavir 的每日剂量为 100mg、ombitasvir 的每日剂量为 25mg)和 dasabuvir(每日两次 250mg)联合利巴韦林(每日 1000 或 1200mg)或匹配安慰剂治疗,为期 12 周的双盲期。主要终点是研究治疗结束后 12 周持续病毒学应答率。主要疗效分析将接受活性治疗方案的患者的这一比率与既往接受过 telaprevir 和聚乙二醇干扰素-利巴韦林治疗的 HCV 基因型 1 感染且无肝硬化的既往治疗患者的历史应答率(65%)进行比较。

结果

共有 394 名患者至少接受了一剂研究药物。在活性治疗组中,297 名接受治疗的患者中有 286 名在治疗后第 12 周达到持续病毒学应答,总体应答率为 96.3%(95%置信区间,94.2 至 98.4)。这一比率与历史对照率相当,并且优于历史对照率。既往复发(86 名患者中有 82 名)患者的应答率为 95.3%,既往部分应答(65 名患者中有 100%)患者的应答率为 100%,既往无应答(146 名患者中有 139 名)患者的应答率为 95.2%。与安慰剂(5.2%)相比,活性治疗方案(13.8%的患者)更常出现瘙痒。由于不良反应,3 名患者(1.0%)停止使用研究药物。活性治疗组分别有 4.7%和 0.3%的患者血红蛋白值为 2 级(8.0 至 <10.0g/dL)和 3 级(6.5 至 <8.0g/dL)。

结论

在既往接受过 HCV 基因型 1 感染治疗的患者中,包括既往无应答的患者,12 周无干扰素联合治疗方案的应答率超过 95%。(由 AbbVie 资助;SAPPHIRE-II ClinicalTrials.gov 编号,NCT01715415。)

相似文献

1
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.ABT-450/r-ombitasvir 和 dasabuvir 联合利巴韦林治疗 HCV。
N Engl J Med. 2014 Apr 24;370(17):1604-14. doi: 10.1056/NEJMoa1401561. Epub 2014 Apr 10.
2
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.ABT-450/r-ombitasvir 和利巴韦林联合治疗 HCV。
N Engl J Med. 2014 Apr 24;370(17):1594-603. doi: 10.1056/NEJMoa1315722. Epub 2014 Apr 10.
3
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.ABT-450、利托那韦、奥比他韦和达沙布韦联合或不联合利巴韦林在治疗慢性丙型肝炎 1b 型感染的有治疗经验的患者中实现了 97%和 100%的持续病毒学应答。
Gastroenterology. 2014 Aug;147(2):359-365.e1. doi: 10.1053/j.gastro.2014.04.045. Epub 2014 May 9.
4
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.ABT-450/r-ombitasvir 和 dasabuvir 联合利巴韦林治疗肝硬化合并丙型肝炎。
N Engl J Med. 2014 May 22;370(21):1973-82. doi: 10.1056/NEJMoa1402869. Epub 2014 Apr 11.
5
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.ABT-450/r-ombitasvir 和 dasabuvir 联合或不联合利巴韦林治疗 HCV。
N Engl J Med. 2014 May 22;370(21):1983-92. doi: 10.1056/NEJMoa1402338. Epub 2014 May 4.
6
An interferon-free antiviral regimen for HCV after liver transplantation.肝移植后 HCV 的无干扰素抗病毒治疗方案。
N Engl J Med. 2014 Dec 18;371(25):2375-82. doi: 10.1056/NEJMoa1408921. Epub 2014 Nov 11.
7
Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.奥比他韦、帕利哌韦/利托那韦联合达沙布韦±利巴韦林治疗丙型肝炎病毒1型感染患者的暴露-疗效分析
Clin Drug Investig. 2016 Aug;36(8):625-35. doi: 10.1007/s40261-016-0407-x.
8
Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.用于丙型肝炎病毒1型感染的奥比他韦/帕利哌韦/利托那韦和达沙布韦片
Ann Pharmacother. 2015 May;49(5):566-81. doi: 10.1177/1060028015570729. Epub 2015 Feb 13.
9
Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).奥比他韦/帕利瑞韦/利托那韦+达沙布韦+利巴韦林用于治疗慢性丙型肝炎病毒1b型感染的肝硬化患者(TURQUOISE-IV研究)
Eur J Gastroenterol Hepatol. 2018 Sep;30(9):1073-1076. doi: 10.1097/MEG.0000000000001166.
10
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.奥比他韦、帕利瑞韦、利托那韦、达沙布韦联合或不联合利巴韦林治疗丙型肝炎病毒基因型 1 或 4 感染合并肝硬化患者(ABACUS):一项前瞻性观察研究。
Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10.

引用本文的文献

1
The Potential of Peptide-Based Inhibitors in Disrupting Protein-Protein Interactions for Targeted Cancer Therapy.基于肽的抑制剂在破坏蛋白质-蛋白质相互作用以进行靶向癌症治疗中的潜力。
Int J Mol Sci. 2025 Mar 28;26(7):3117. doi: 10.3390/ijms26073117.
2
Hepatitis C Virus Resistance-Associated Substitutions in Mexico.墨西哥丙型肝炎病毒耐药相关替代位点
Viruses. 2025 Jan 25;17(2):169. doi: 10.3390/v17020169.
3
Mechanosignaling via Integrins: Pivotal Players in Liver Fibrosis Progression and Therapy.通过整合素的机械信号传导:肝纤维化进展和治疗中的关键因素
Cells. 2025 Feb 12;14(4):266. doi: 10.3390/cells14040266.
4
ABT-333 (Dasabuvir) Increases Action Potential Duration and Provokes Early Afterdepolarizations in Canine Left Ventricular Cells via Inhibition of I.ABT-333(达沙布韦)通过抑制I增加犬左心室细胞的动作电位持续时间并引发早期后去极化。
Pharmaceuticals (Basel). 2023 Mar 25;16(4):488. doi: 10.3390/ph16040488.
5
Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.直接作用抗病毒药物治疗优化十年及慢性丙型肝炎患者特征变化。
World J Gastroenterol. 2023 Feb 14;29(6):949-966. doi: 10.3748/wjg.v29.i6.949.
6
A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania.一项真实世界研究,比较在罗马尼亚布加勒斯特 Fundeni 临床学院的 587 例慢性丙型肝炎患者中,使用帕利瑞韦/奥比他韦/利托那韦联合或不联合利巴韦林的安全性和疗效。
Med Sci Monit. 2022 Jul 5;28:e936706. doi: 10.12659/MSM.936706.
7
Metformin improves the therapeutic efficacy of low-dose albendazole against experimental alveolar echinococcosis.二甲双胍可提高低剂量阿苯达唑治疗实验性细粒棘球蚴病的疗效。
Parasitology. 2022 Jan;149(1):138-144. doi: 10.1017/S0031182021001633. Epub 2021 Oct 20.
8
The Patient Bomb: Sustained Viral Response after Hepatitis C in Cirrhosis.患者炸弹:肝硬化丙型肝炎后的持续病毒学应答
GE Port J Gastroenterol. 2020 Apr;27(3):147-148. doi: 10.1159/000504718. Epub 2020 Feb 5.
9
Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience.真实世界中,ombitasvir/paritaprevir/ritonavir±dasabuvir±利巴韦林联合治疗方案对丙型肝炎病毒 1 型或 4 型感染患者的疗效、安全性和临床结局:土耳其经验。
Turk J Gastroenterol. 2020 Apr;31(4):305-317. doi: 10.5152/tjg.2020.19197.
10
Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial.在蛋白酶抑制剂失败后使用奥比他韦/帕利瑞韦/利托那韦和达沙布韦±利巴韦林 - 一项前瞻性多中心试验。
BMC Infect Dis. 2020 Apr 3;20(1):264. doi: 10.1186/s12879-020-4921-3.